[go: up one dir, main page]

WO2012011129A3 - Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt - Google Patents

Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt Download PDF

Info

Publication number
WO2012011129A3
WO2012011129A3 PCT/IN2011/000485 IN2011000485W WO2012011129A3 WO 2012011129 A3 WO2012011129 A3 WO 2012011129A3 IN 2011000485 W IN2011000485 W IN 2011000485W WO 2012011129 A3 WO2012011129 A3 WO 2012011129A3
Authority
WO
WIPO (PCT)
Prior art keywords
dihydroxyhept
methylsulfonyl
pyrimidin
fluorophenyl
iso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2011/000485
Other languages
French (fr)
Other versions
WO2012011129A2 (en
Inventor
Manne Satyanarayana Reddy
Srinivasan Thirumalai Rajan
Maramreddy Sahadeva Reddy
Ningam Srinivasa Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSN Laboratories Pvt Ltd
Original Assignee
MSN Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSN Laboratories Pvt Ltd filed Critical MSN Laboratories Pvt Ltd
Publication of WO2012011129A2 publication Critical patent/WO2012011129A2/en
Publication of WO2012011129A3 publication Critical patent/WO2012011129A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are novel polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium.
PCT/IN2011/000485 2010-07-22 2011-07-21 Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt Ceased WO2012011129A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2088CH2010 2010-07-22
IN2088/CHE/2010 2010-07-22

Publications (2)

Publication Number Publication Date
WO2012011129A2 WO2012011129A2 (en) 2012-01-26
WO2012011129A3 true WO2012011129A3 (en) 2012-03-15

Family

ID=45497235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000485 Ceased WO2012011129A2 (en) 2010-07-22 2011-07-21 Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt

Country Status (1)

Country Link
WO (1) WO2012011129A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014050874A1 (en) * 2012-09-27 2014-04-03 東和薬品株式会社 Novel crystalline form of rosuvastatin calcium and production method therefor
PL3445751T3 (en) * 2016-04-18 2023-09-18 Morepen Laboratories Limited New polymorphic form of crystalline rosuvastatin calcium&novel processes for crystalline as well as amorphous rosuvastatin calcium
CN105837516B (en) * 2016-05-16 2018-07-10 山东新时代药业有限公司 A kind of rosuvastain calcium crystal form and preparation method thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000049014A1 (en) * 1999-02-17 2000-08-24 Astrazeneca Ab Process for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate
WO2003097614A2 (en) * 2002-05-21 2003-11-27 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
WO2004052867A1 (en) * 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
WO2004108691A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Uk Limited Improved production of rosuvastatin calcium salt
WO2005051921A1 (en) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
CN1733737A (en) * 2005-08-22 2006-02-15 鲁南制药集团股份有限公司 Preparation method of rosuvastatin and salt thereof
CN1763015A (en) * 2004-10-22 2006-04-26 四川抗菌素工业研究所有限公司 Preparation method and intermediate of rosuvastatin and its pharmaceutical salts
WO2006100689A1 (en) * 2005-03-22 2006-09-28 Unichem Laboratories Limited Process for preparation of rosuvastatin
WO2007017117A1 (en) * 2005-07-28 2007-02-15 Lek Pharmaceuticals D.D. Process for the synthesis of rosuvastatin calcium
WO2008044243A2 (en) * 2006-10-09 2008-04-17 Manne Satyanarayana Reddy Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
US20080091014A1 (en) * 2005-01-19 2008-04-17 Anhui Quingyun Pharmaceutical And Chemical Co., Ltd. Synthetic Method and Intermediates of Rosuvastatin Calcium and Preparation Methods of Intermediates
WO2008065410A1 (en) * 2006-12-01 2008-06-05 Astrazeneca Uk Limited Process for the preparation of rosuvastatin
CN101376647A (en) * 2007-08-31 2009-03-04 中山奕安泰医药科技有限公司 Synthetic method for synthesizing rosuvastatin intermediate and rosuvastatin
CA2725052A1 (en) * 2008-05-27 2009-12-03 Changzhou Pharmaceutical Factory Co., Ltd. Preparation method of rosuvastatin calcium and its intermediates

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000049014A1 (en) * 1999-02-17 2000-08-24 Astrazeneca Ab Process for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate
WO2003097614A2 (en) * 2002-05-21 2003-11-27 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
WO2004052867A1 (en) * 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
WO2004108691A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Uk Limited Improved production of rosuvastatin calcium salt
WO2005051921A1 (en) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
CN1763015A (en) * 2004-10-22 2006-04-26 四川抗菌素工业研究所有限公司 Preparation method and intermediate of rosuvastatin and its pharmaceutical salts
US20080091014A1 (en) * 2005-01-19 2008-04-17 Anhui Quingyun Pharmaceutical And Chemical Co., Ltd. Synthetic Method and Intermediates of Rosuvastatin Calcium and Preparation Methods of Intermediates
WO2006100689A1 (en) * 2005-03-22 2006-09-28 Unichem Laboratories Limited Process for preparation of rosuvastatin
WO2007017117A1 (en) * 2005-07-28 2007-02-15 Lek Pharmaceuticals D.D. Process for the synthesis of rosuvastatin calcium
CN1733737A (en) * 2005-08-22 2006-02-15 鲁南制药集团股份有限公司 Preparation method of rosuvastatin and salt thereof
WO2008044243A2 (en) * 2006-10-09 2008-04-17 Manne Satyanarayana Reddy Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2008065410A1 (en) * 2006-12-01 2008-06-05 Astrazeneca Uk Limited Process for the preparation of rosuvastatin
CN101376647A (en) * 2007-08-31 2009-03-04 中山奕安泰医药科技有限公司 Synthetic method for synthesizing rosuvastatin intermediate and rosuvastatin
CA2725052A1 (en) * 2008-05-27 2009-12-03 Changzhou Pharmaceutical Factory Co., Ltd. Preparation method of rosuvastatin calcium and its intermediates

Also Published As

Publication number Publication date
WO2012011129A2 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
TWI341310B (en) Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
HRP20190012T1 (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
WO2009157014A3 (en) A process for preparing hmg-coa reductase inhibitors and intermediates
MY142615A (en) Crystalline form of bis [ (e)-7-4(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6 -enoic acid] calcium salt
IS8478A (en) Process for the preparation of the calcium salt of rosuvatatin (E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] (3R, 5S) -3,5- dihydroxyhept-6-enoic acid and its crystalline intermediates
IL227904A (en) Formation of n-protected bis-3,6-(4-aminoalkyl)-2,5-diketopiperazine
CU23886B1 (en) PIRROLO DERIVATIVES [2,3-D] PYRIMIDINE AS INHIBITORS OF KINASE PROTEINS B
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
PH12014500107A1 (en) N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
ZA200807158B (en) Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1, 4-dihydro-8-methoxy-4-oxo-3-quinolinecaroxylic acid
WO2011099764A3 (en) Novel pyrimidine derivative for inhibiting the growth of cancer cells
EA201390771A1 (en) METHOD OF OBTAINING PHARMACEUTICAL INTERMEDIATE COMPOUNDS OF HIGH PURITY
WO2012011129A3 (en) Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
PL1704144T3 (en) A method of preparation of the hemi-calcium salt of (e)-7- [4-(4-fluorophenyl)-6-isopropyl-2- [me thyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxy-6-heptenoic acid
ATE553098T1 (en) METHOD FOR PRODUCING ROSUVASTATIN CALCIUM
PL386051A1 (en) Stable, oral compound pharmaceutical containing pharmaceutically permissible content of [(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3R,5S)-3,5-dihydroxy-hept-6-enoate acid salt
WO2012063115A3 (en) Process for the preparation of rosuvastatin calcium via novel amine intermediate
WO2012073054A3 (en) Method for preparing rosuvastatin salts
MX2010011006A (en) New salt of a pyrimidin derivative.
HK40119285A (en) Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt
WO2009091346A3 (en) Stable pharmaceutical formulation and preparation methods
HK1192883A (en) Formation of n-protected bis-3,6-(4-aminoalkyl) -2,5,diketopiperazine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11809383

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11809383

Country of ref document: EP

Kind code of ref document: A2